Models of new antioestrogen action in vivo: primary tumours
Authors:
- 30 June 1996
- journal article
- Published by Elsevier in The Breast
- Vol. 5 (3) , 186-191
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor.Endocrinology, 1995
- Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cellsEndocrine-Related Cancer, 1995
- Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor statusBritish Journal of Cancer, 1993
- Action of ?pure? antiestrogens in inhibiting estrogen receptor actionBreast Cancer Research and Treatment, 1993
- Effect of Estrogen and Antiestrogens on Cell Proliferation and Synthesis of Secreted Proteins in the Human Breast Cancer Cell Line MCF-7 and a Tamoxifen Resistant Variant Subline, AL-1Acta Oncologica, 1992
- Tamoxifen for breast cancer: Associated endometrial cancerCancer, 1990
- ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERSThe Lancet, 1989
- The Christie hospital adjuvant tamoxifen trial – status at 10 yearsBritish Journal of Cancer, 1988
- Novel antioestrogens without partial agonist activityJournal of Steroid Biochemistry, 1988
- Estrogen Control of Progesterone Receptor in Human Breast Cancer: Role of Estradiol and Antiestrogen*Endocrinology, 1978